Lastly, in order to explore whether targeting this identified YAP-TEAD/LOX axis is a potential therapy for patients with IPF, we examined the anti-fibrotic activity of VP in a highly complex ex vivo human 3D tissue culture model using precision cut-lung slices (PCLS). Here, LOX is linked to idiopathic pulmonary fibrosis.